Emerging evidence has shown that therapeutic strategies based on the modulation of TGF-β in AMD could constitute a promising avenue to treat this major cause of blindness by regulating several pathophysiological processes involved in the disease, including fibrosis, the immune response, and RPE function as well as the angiogenic response. The gene discussed is TGFB1; the disease is age-related macular degeneration.